Delamanid

Delamanid is a nitroimidazole-oxazole compound used for the treatment of multidrug-resistant tuberculosis (MDR-TB) as part of an appropriate combination regimen. It inhibits mycolic acid synthesis, disrupting the bacterial cell wall of Mycobacterium tuberculosis. Mediocon Inc supplies pharmaceutical-grade Delamanid meeting IP, BP, EP, and USP standards.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Multidrug-resistant tuberculosis (MDR-TB)
• Extensively drug-resistant TB (XDR-TB)
• Combination anti-TB regimens
• TB R&D and clinical research

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings